Cryolife Inc (NYSE:CRY) VP Scott B. Capps sold 2,000 shares of Cryolife stock in a transaction on Friday, May 31st. The shares were sold at an average price of $28.55, for a total transaction of $57,100.00. Following the completion of the transaction, the vice president now directly owns 141,079 shares of the company’s stock, valued at approximately $4,027,805.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

CRY opened at $28.75 on Tuesday. Cryolife Inc has a fifty-two week low of $23.99 and a fifty-two week high of $36.05. The company has a debt-to-equity ratio of 0.86, a current ratio of 4.90 and a quick ratio of 3.69. The firm has a market capitalization of $1.07 billion, a price-to-earnings ratio of 110.58 and a beta of 0.61.

Cryolife (NYSE:CRY) last released its quarterly earnings data on Tuesday, April 30th. The medical equipment provider reported $0.04 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.04. Cryolife had a negative net margin of 0.09% and a positive return on equity of 3.79%. The company had revenue of $67.50 million during the quarter, compared to analysts’ expectations of $66.37 million. During the same quarter in the previous year, the company earned $0.02 earnings per share. The firm’s revenue for the quarter was up 9.0% on a year-over-year basis. As a group, equities analysts anticipate that Cryolife Inc will post 0.31 EPS for the current year.

A number of research firms have weighed in on CRY. Needham & Company LLC reaffirmed a “hold” rating on shares of Cryolife in a report on Wednesday, May 1st. TheStreet raised shares of Cryolife from a “c” rating to a “b-” rating in a report on Wednesday, May 1st. Canaccord Genuity reaffirmed a “buy” rating and issued a $35.00 price objective (up previously from $32.00) on shares of Cryolife in a report on Wednesday, May 1st. ValuEngine cut shares of Cryolife from a “strong-buy” rating to a “buy” rating in a report on Wednesday, May 15th. Finally, Zacks Investment Research cut shares of Cryolife from a “hold” rating to a “sell” rating in a report on Wednesday, February 20th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Cryolife currently has a consensus rating of “Buy” and an average target price of $31.91.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CRY. Advisors Asset Management Inc. purchased a new stake in shares of Cryolife during the fourth quarter worth about $32,000. Bessemer Group Inc. purchased a new stake in shares of Cryolife during the fourth quarter worth about $60,000. LS Investment Advisors LLC increased its stake in shares of Cryolife by 126.0% during the fourth quarter. LS Investment Advisors LLC now owns 2,581 shares of the medical equipment provider’s stock worth $73,000 after purchasing an additional 1,439 shares in the last quarter. US Bancorp DE increased its stake in shares of Cryolife by 25.8% during the first quarter. US Bancorp DE now owns 2,540 shares of the medical equipment provider’s stock worth $74,000 after purchasing an additional 521 shares in the last quarter. Finally, Quantamental Technologies LLC purchased a new stake in shares of Cryolife during the first quarter worth about $75,000. 71.20% of the stock is owned by institutional investors.

WARNING: This news story was originally published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.watchlistnews.com/cryolife-inc-cry-vp-sells-57100-00-in-stock/3030961.html.

Cryolife Company Profile

CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.

Featured Article: Is it better to buy a fund with a higher or lower NAV?

Insider Buying and Selling by Quarter for Cryolife (NYSE:CRY)

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.